Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change
24/07/26	€0.3620	0.00%
23/07/26	€0.3620	0.00%
22/07/26	€0.3620	0.00%
21/07/26	€0.3620	0.00%
20/07/26	€0.3620	0.00%

Real-time BOERSE MUENCHEN

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3770EUR

Average target price

1.000EUR

Spread / Average Target

+165.25%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time BOERSE MUENCHEN Other stock markets 18:13:47 24/07/2026 BST			5-day change	1st Jan Change
0.3620 ^EUR	0.00%		0.00%	+21.68%

07-01	Nicox Submits NCX 470 New Drug Application In The United States	CI
07-01	Nicox files U.S. marketing approval application

Market Cap	33.23M 37.83M 30.9M 28.35M 53.27M 3.64B 54.1M 367M 143M 1.79B 142M 139M 6.19B	P/E 2026 *	-5.39x	P/E 2027 *	37.7x
Enterprise Value	33.23M 37.83M 30.9M 28.35M 53.27M 3.64B 54.1M 367M 143M 1.79B 142M 139M 6.19B	EV / Sales 2026 *	11.1x	EV / Sales 2027 *	3.32x
Free-Float	99.65%	Yield 2026 *	-	Yield 2027 *	-

07-01	Nicox Submits NCX 470 New Drug Application In The United States	CI
07-01	Nicox files U.S. marketing approval application
06-23	Nicox Bags EUR6 Million Shareholder Loan	MT
06-23	Nicox Secures Backing From a Shareholder and Financial Partner
06-18	Nicox Receives Positive Feedback from China
06-18	Nicox Announces Positive Pre-Submission Regulatory Feedback in China Supporting NDA Filing for NCX 470	CI
04-29	Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-24	Nicox SA Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting	CI
02-24	Edenred, Forvia, Freelance.com... Key Stocks to Watch Today in Paris -
02-24	Nicox Reports Positive Phase 3 Results for NCX 470
02-16	Nicox, Sanofi, Valneva... Stocks to Watch Today in Paris
02-16	Nicox Moves Forward with U.S. Health Authorities for Its NCX 470
01-05	Nicox Strengthens Its Financial Position

07-01	Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment	GL
06-23	Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company	GL
06-18	Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470	GL
06-08	Reminder: Nicox June 2024 Warrants will expire June 19, 2026	GL
06-03	Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative	GL

Nicox SA Share Price BOERSE MUENCHEN

Stocks

NXOA

FR0013018124

Pharmaceuticals

Valuation: Nicox SA

Chart: Nicox SA

Latest news : Nicox SA

Press Releases: Nicox SA

News in other languages: Nicox SA

Quotes and Performance

Course Extremes

Managers and Directors: Nicox SA

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

07-01	Bourse : Schneider se renforce dans l'IA, Air Liquide investit pour SK Hynix, Nike déçoit
07-01	Nicox dépose une demande d'autorisation de mise sur le marché aux Etats-Unis
07-01	La Bourse s'habitue à tout
07-01	Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé
06-23	Bourse : Sanofi enchaîne les AMM, Prysmian enchaîne les contrats, l'IA enchaîne les dépenses

Current month	-2.69%
1 month	-2.82%
3 months	-9.61%
6 months	-4.74%
Current year	+21.68%

Manager	Title	Age	Since
Gavin Spencer CEO	Chief Executive Officer	55	27/02/2024
Sandrine Gestin DFI	Director of Finance/CFO	58	31/12/2014
Doug Hubatsch CTO	Chief Tech/Sci/R&D Officer	-	12/12/2021

Director	Title	Age	Since
Gavin Spencer BRD	Director/Board Member	55	07/04/2024
Damian Marron CHM	Chairman	64	15/07/2024
Marc Bozec BRD	Director/Board Member	-	15/07/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NICOX SA	0.00%	0.00%	+12.25%	-18.83%	37.78M
MERCK & CO., INC.	+0.59%	+2.85%	+55.91%	+20.54%	322B
MERCK KGAA	-0.07%	+2.09%	+22.76%	-11.68%	68.84B
HALOZYME THERAPEUTICS, INC.	+1.51%	+5.48%	+39.65%	+91.94%	9.59B
KYOWA KIRIN CO., LTD.	+0.93%	-1.04%	+3.79%	-3.09%	8.29B
SK BIOPHARMACEUTICALS CO., LTD.	+1.13%	+1.51%	-20.75%	-5.62%	4.23B
BETTA PHARMACEUTICALS CO., LTD.	-4.00%	-10.40%	-7.02%	+17.32%	3.77B
YUHAN CORPORATION	+4.90%	+5.79%	-40.18%	+17.38%	3.61B
SUPERNUS PHARMACEUTICALS, INC.	-1.38%	-3.14%	+41.64%	+54.84%	2.74B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-4.07%	-9.67%	-0.61%	-13.86%	2.13B
Average	-0.05%	+1.16%	+10.75%	+14.89%	47.27B
Weighted average by Cap.	+0.46%	+2.62%	+46.65%	+16.21%

	2026 *	2027 *
Net sales	3M 3.42M 2.79M 2.56M 4.81M 329M 4.88M 33.13M 12.94M 162M 12.82M 12.55M 559M	10M 11.39M 9.3M 8.53M 16.03M 1.1B 16.28M 110M 43.14M 539M 42.74M 41.82M 1.86B
Net income	-6M -6.83M -5.58M -5.12M -9.62M -658M -9.77M -66.26M -25.89M -323M -25.64M -25.09M -1.12B	1M 1.14M 930K 853K 1.6M 110M 1.63M 11.04M 4.31M 53.91M 4.27M 4.18M 186M
Net Debt	-	-

1 week	0.36	0.38
1 month	0.36	0.39
3 years	0.15	0.65
5 years	0.15	3.82